Research Article
Efficacy and Safety of Ningmitai Capsules in Patients with Chronic Epididymitis: A Prospective, Parallel Randomized Controlled Clinical Trial
Table 3
Clinical efficacy rates after 2 and 4 weeks of treatment.
| | | 2 weeks | 4 weeks | | LVX | NMT | LVX + NMT | LVX | NMT | LVX + NMT |
| | n | 36 | 40 | 36 | 36 | 40 | 36 | | Clinical efficacy, no. (%) | | | | | | | | Effective | 3 (8.33) | 22 (55.00) | 22 (61.11) | 30 (83.33) | 32 (80.00) | 35 (97.22) | | Ineffective | 33 (91.67) | 18 (45.00) | 14 (38.89) | 6 (16.67) | 8 (20.00) | 1 (2.78) | | χ2△ | — | 18.69 | 22.12 | — | 0.1401 | 2.5320 | | value△ | — | <0.0001 | <0.0001 | — | 0.7082 | 0.1116 |
|
|
LVX, levofloxacin; NMT, Ningmitai. △Compared with the LVX group.
|
